Rodney Sinclair
YOU?
Author Swipe
View article: Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA)
Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA) Open
View article: Description of the 3 Tranquillo Phase 3 clinical program study designs to assess ritlecitinib treatment in adults and adolescents with nonsegmental vitiligo
Description of the 3 Tranquillo Phase 3 clinical program study designs to assess ritlecitinib treatment in adults and adolescents with nonsegmental vitiligo Open
No systemic treatments are currently approved for nonsegmental vitiligo (NSV). In a Phase 2b study (NCT03715829), the JAK3/TEC family kinase inhibitor ritlecitinib 50 mg (± a 100- or 200-mg loading dose) once-daily (QD) was effective and w…
View article: Long-Term Efficacy and Complete Scalp Hair Regrowth in Patients With Alopecia Areata Receiving Ritlecitinib 50 mg QD Up to 3 Years in the ALLEGRO Clinical Trial Program
Long-Term Efficacy and Complete Scalp Hair Regrowth in Patients With Alopecia Areata Receiving Ritlecitinib 50 mg QD Up to 3 Years in the ALLEGRO Clinical Trial Program Open
Introduction In clinical trials for alopecia areata (AA), achievement of Severity of Alopecia Tool (SALT) score ≤20 and ≤10 (≤20% and ≤10% scalp hair loss) are commonly reported, but achievement of SALT score 0 (complete scalp hair regrowt…
View article: Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata Open
View article: Improvement in Patient‐Reported Emotional Symptoms and Activity Limitations due to Hair Loss in Patients With Alopecia Areata Treated With Ritlecitinib: Additional Analyses From <scp>ALLEGRO</scp>‐2b/3
Improvement in Patient‐Reported Emotional Symptoms and Activity Limitations due to Hair Loss in Patients With Alopecia Areata Treated With Ritlecitinib: Additional Analyses From <span>ALLEGRO</span>‐2b/3 Open
Background Patients with alopecia areata (AA) in ALLEGRO‐2b/3 (NCT03732807) had clinically significant hair regrowth and patient‐reported improvements with ritlecitinib versus placebo, but patient‐reported improvements in AA Patient Priori…
View article: Clinicopathological features and treatment outcomes of fibrosing alopecia in a pattern distribution: a multicentre cohort study
Clinicopathological features and treatment outcomes of fibrosing alopecia in a pattern distribution: a multicentre cohort study Open
Background Fibrosing alopecia in a pattern distribution (FAPD) is a lymphocytic primary cicatricial alopecia first described in 2000. However, to date, the FAPD literature remains sparse. Objectives To identify clinicopathological features…
View article: Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement
Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement Open
Over 5000 patients are newly diagnosed with Alopecia areata (AA) in Australia each year. AA severity varies from a single small patch to complete loss of scalp hair, body hair including eyelashes and eyebrows. Approximately 40% of affected…
View article: Correction to: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Correction to: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program Open
View article: Criteria for Commencing and Continuing Subsidised Janus Kinase Inhibitor Therapy in Australian Alopecia Areata Patients—Results From an Australian Expert Consensus Exercise
Criteria for Commencing and Continuing Subsidised Janus Kinase Inhibitor Therapy in Australian Alopecia Areata Patients—Results From an Australian Expert Consensus Exercise Open
Background/Objectives Janus kinase inhibitors (JAKis) have been approved by the Therapeutic Goods Administration for severe alopecia areata (AA) in Australia. However, access is limited as JAKis are not currently subsidised on the Pharmace…
View article: You cannot go bald without first losing your hair: telogen effluvium is a precursor to, prerequisite for and potentially an incitant to common baldness in men
You cannot go bald without first losing your hair: telogen effluvium is a precursor to, prerequisite for and potentially an incitant to common baldness in men Open
Background Telogen effluvium (TE) is defined by an increased ratio of hairs in telogen to hairs in anagen. Diagnosis is not contingent on a self-reported quantum of telogen shedding. Androgenetic alopecia (AGA) is diagnosed histologically …
View article: Statement from the frontal fibrosing alopecia international expert alliance: <scp>SOFFIA</scp> 2024
Statement from the frontal fibrosing alopecia international expert alliance: <span>SOFFIA</span> 2024 Open
Background As the incidence of frontal fibrosing alopecia (FFA) continues to rise, there is a need for an optimal treatment algorithm for FFA. Objective To produce an international consensus statement on the treatment modalities and progno…
View article: International collaboration and rapid harmonization across dermatologic COVID-19 registries
International collaboration and rapid harmonization across dermatologic COVID-19 registries Open
View article: Patient satisfaction with hair regrowth in a study of ritlecitinib: a plain language summary
Patient satisfaction with hair regrowth in a study of ritlecitinib: a plain language summary Open
What is this summary about? Alopecia areata (‘AA’ for short) is an autoimmune disease that causes a person to lose their hair. Ritlecitinib is a medication approved to treat severe AA. It blocks parts of the body’s defense system that play…
View article: COLLAB: A Global Survey of Clinical and Laboratory Assessment in Alopecia Areata by Hair Specialists
COLLAB: A Global Survey of Clinical and Laboratory Assessment in Alopecia Areata by Hair Specialists Open
Background Alopecia areata (AA) is a common non‐scarring alopecia. Data continue to emerge on associations with autoimmune and other conditions. Janus kinase inhibitors (JAKi) are increasingly used to treat AA. Objectives The aim was to as…
View article: Learning from disease registries during a pandemic: Moving toward an international federation of patient registries
Learning from disease registries during a pandemic: Moving toward an international federation of patient registries Open
View article: Psychosocial and Occupational Burden on Caregivers of Adolescents With Alopecia Areata in Australia
Psychosocial and Occupational Burden on Caregivers of Adolescents With Alopecia Areata in Australia Open
We conducted a noninterventional, cross‐sectional online survey in Australia from April to July 2023 to investigate the impact of alopecia areata (AA) on psychosocial well‐being, work productivity and quality of life among caregivers of ad…
View article: Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment
Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment Open
View article: Summation and recommendations for the safe and effective use of topical and oral minoxidil
Summation and recommendations for the safe and effective use of topical and oral minoxidil Open
Provision of basic knowledge of the key aspects of the use of topical or oral minoxidil to insure safe and effective use of either in treating hair loss.
View article: Prediction of Long-term Scalp Hair Regrowth at 24 Months in Patients with Alopecia Areata Receiving Ritlecitinib Treatment in the ALLEGRO Clinical Trial Program
Prediction of Long-term Scalp Hair Regrowth at 24 Months in Patients with Alopecia Areata Receiving Ritlecitinib Treatment in the ALLEGRO Clinical Trial Program Open
None.
View article: Pericardial Disorders Occurring during Open Label Study of 3747 Patients Treated with Systemic Minoxidil
Pericardial Disorders Occurring during Open Label Study of 3747 Patients Treated with Systemic Minoxidil Open
View article: Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the <scp>ALLEGRO</scp> clinical development programme
Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the <span>ALLEGRO</span> clinical development programme Open
Background Ritlecitinib, an oral JAK3/TEC family kinase inhibitor, demonstrated efficacy over 48 weeks in patients with alopecia areata (AA) in the ALLEGRO phase 2b/3 study. Objectives This post hoc analysis evaluated individual Severity o…
View article: Scalp hair parameter changes in transgender individuals commencing gender-affirming hormone therapy: A 24-week prospective observational study
Scalp hair parameter changes in transgender individuals commencing gender-affirming hormone therapy: A 24-week prospective observational study Open
View article: Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the <scp>ALLEGRO</scp>‐<scp>LT</scp> phase 3, open‐label study
Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the <span>ALLEGRO</span>‐<span>LT</span> phase 3, open‐label study Open
Background ALLEGRO‐LT is an ongoing, long‐term, open‐label, multicentre, phase 3 study of ritlecitinib in adults and adolescents with alopecia areata (AA). Objectives To evaluate ritlecitinib safety and efficacy through Month 24 in patient…
View article: Evidence-Based Data on How Long to Treat to Achieve Treatment Response With Baricitinib in Severe Alopecia Areata
Evidence-Based Data on How Long to Treat to Achieve Treatment Response With Baricitinib in Severe Alopecia Areata Open
Introduction: Previous data on baricitinib treatment in severe alopecia areata (AA) has shown that treatment response varies by baseline disease severity and by duration of current episode. In general, hair regrowth response varies, and cl…
View article: Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss
Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss Open
Importance The results of small studies suggest that off-label use of low-dose oral minoxidil (LDOM) may be safe and effective for patients with hair loss, but larger trials and standardized guidelines are lacking. Objective To create an e…
View article: Characterizing Lipid Changes and Use of Lipid-Lowering Medications in Patients With Alopecia Areata Treated With Baricitinib: Integrated Results From the BRAVE-AA1 and -AA2 Clinical Trials
Characterizing Lipid Changes and Use of Lipid-Lowering Medications in Patients With Alopecia Areata Treated With Baricitinib: Integrated Results From the BRAVE-AA1 and -AA2 Clinical Trials Open
Introduction. Elevations in total cholesterol, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) can occur with baricitinib treatment, consistent with a class effect of JAK inhibitors. In this an…
View article: Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial
Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial Open
View article: Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial
Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial Open
Hair regrowth was sustained through week 48 in patients with response at week 24. Up to one-third of patients who did not meet target efficacy at week 24 achieved response with continued ritlecitinib treatment.
View article: Efficacy and safety of ritlecitinib, an oral <scp>JAK3</scp>/<scp>TEC</scp> family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis
Efficacy and safety of ritlecitinib, an oral <span>JAK3</span>/<span>TEC</span> family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis Open
This post‐hoc analysis of the ALLEGRO phase 2b/3 study (NCT03732807) evaluated the efficacy and safety of ritlecitinib, an oral Janus kinase 3/TEC family kinase inhibitor, in patients with alopecia totalis (AT) and alopecia universalis (AU…
View article: Patient-Reported Satisfaction with Hair Regrowth in a Study of Ritlecitinib in Alopecia Areata: Results from ALLEGRO-2b/3
Patient-Reported Satisfaction with Hair Regrowth in a Study of Ritlecitinib in Alopecia Areata: Results from ALLEGRO-2b/3 Open
Introduction: Patients with alopecia areata (AA) report high levels of dissatisfaction with commonly used treatments. Patient-reported outcomes are essential to understanding patients’ experiences with AA treatments. The obje…